SCHEMBL2032051

SCHEMBL2032051

O=C(O)c1cc(Cl)ccc1-c1ccc2ncccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.61
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ HTT P42858 1/20 0.54
▸ POLB P06746 1/20 0.53
▸ AKR1C3 P42330 1/20 0.51
▸ AKR1C2 P52895 1/20 0.51
▸ PTGES O14684 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ ALOX5 P09917 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ DHODH Q02127 6/20 0.47
▸ NR4A2 P43354 1/20 0.46
▸ AR P10275 1/20 0.46
▸ DOT1L Q8TEK3 1/20 0.46
▸ PFKFB3 Q16875 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30838469 0.85 MCL1 (0.66) MCL1NPC1RAB9APOLBAKR1C3
SCHEMBL27758566 0.82 NPC1 (0.53) MCL1NPC1RAB9AHTTPOLB
SCHEMBL2030204 0.82 KDM4E (0.48) MCL1NPC1RAB9AHTTPOLB
SCHEMBL29236146 0.80 ACMSD (0.55) PTGESALDH1A1ALOX5CYP2C9HPGD
SCHEMBL420345 0.78 SERPINE1 (0.69) MCL1NPC1RAB9AHTTAKR1C3
SCHEMBL418849 0.77 SERPINE1 (0.67) MCL1NPC1RAB9AHTTAKR1C3
SCHEMBL10784946 0.76 NPC1 (0.78) MCL1NPC1RAB9AHTTPOLB
SCHEMBL359841 0.75 NR4A2 (0.70) NPC1RAB9AHTTPOLBALDH1A1
SCHEMBL27771531 0.75 AR (0.57) MCL1NPC1RAB9AHTTPOLB
SCHEMBL15057250 0.75 ALDH1A1 (0.53) RAB9AAKR1C3AKR1C2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2073811-B1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2015-03-11 — — EP disclosed
US-8586565-B2 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2013-11-19 — — US disclosed
CN-101553233-B Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS LLC 2013-05-29 — — CN disclosed
WO-2013036232-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-14 — — WO disclosed
US-20120225057-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-09-06 — — US disclosed
US-20110136760-A1 Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases DECIPHERA PHARMACEUTICALS, LLC 2011-06-09 — — US disclosed
US-7790756-B2 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2010-09-07 — — US disclosed
CN-101553233-A Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-10-07 — — CN disclosed
EP-2073811-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-07-01 — — EP disclosed
WO-2008046003-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-04-17 — — WO disclosed
US-20080090856-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225057-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES ABL1, MCL1, ABL2 MCL1 2/4885NPC1 3601/4885RAB9A 1325/4885
US-20080090856-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES MYLK3, MYLK, CDK3 MCL1 388/4885NPC1 3414/4885RAB9A 1929/4885
US-20110136760-A1 Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases MYLK3, MYLK, CDK3 MCL1 388/4885NPC1 3414/4885RAB9A 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback